Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28007983 | 0.96 | IDO1 (0.44) | IDO1CA12CA1CA2CA4 | |
| SCHEMBL30719614 | 0.86 | IDO1 (0.57) | IDO1CA12CA1CA2CA4 | |
| SCHEMBL1891196 | 0.86 | IDO1 (0.57) | IDO1CA12CA1CA2CA4 | |
| SCHEMBL357145 | 0.85 | CA1 (0.61) | IDO1CA12CA1CA2CA4 | |
| SCHEMBL31116611 | 0.85 | CA1 (0.61) | IDO1CA12CA1CA2CA4 | |
| SCHEMBL7527797 | 0.84 | IDO1 (0.55) | IDO1CA12CA1CA2CA4 | |
| SCHEMBL30751956 | 0.84 | IDO1 (0.46) | IDO1CA12CA1CA2CA4 | |
| SCHEMBL12473426 | 0.80 | CA1 (0.55) | IDO1CA12CA1CA2CA4 | |
| SCHEMBL30952013 | 0.79 | NQO1 (0.48) | CA12CA1CA2CA4CA7 | |
| SCHEMBL28111436 | 0.79 | SMN1; SMN2 (0.46) | IDO1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158427-A1 | RED-LIGHT IRIDIUM COMPLEX AND USE THEREOF | PHICHEM CORPORATION (CN) | 2024-05-16 | — | — | US | disclosed |
| CN-115716853-A | Red light iridium complex and application thereof | 上海飞凯材料科技股份有限公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | disclosed |
| CN-106478358-A | A kind of organic photoelectrical material containing spirane structure and its application | 中节能万润股份有限公司 | 2017-03-08 | — | — | CN | disclosed |
| US-7144898-B2 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1506190-B1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | HOFFMANN LA ROCHE (CH) | 2006-06-14 | — | — | EP | disclosed |
| EP-1242411-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | LILLY CO ELI (US) | 2006-03-08 | — | — | EP | disclosed |
| US-7005432-B2 | Substituted imidazol-pyridazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-20050272786-A1 | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents | WYETH (US) | 2005-12-08 | — | — | US | disclosed |
| US-6960607-B2 | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents | WYETH (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1250336-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-1248786-A1 | BENZOFURAN DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-16 | — | — | EP | disclosed |
| EP-1246822-A1 | BENZOFURAN DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1242419-A1 | AZABICYCLO 3.2.1]OCTANE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1242411-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | ELI LILLY AND COMPANY (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046187-A1 | AZABICYCLO[3.2.1]OCTANE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046179-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046186-A1 | BENZOFURAN DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046177-A1 | BENZOFURAN DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046181-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158427-A1 | RED-LIGHT IRIDIUM COMPLEX AND USE THEREOF | IK, F10, DRD3 | IDO1 143/4885CA12 869/4885CA1 1694/4885 |
| US-20050272786-A1 | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents | ESR1, ESRRA, ESR2 | IDO1 4229/4885CA12 3074/4885CA1 2661/4885 |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | IDO1 2424/4885CA12 4751/4885CA1 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.